Added Value of Systemic Inflammation Markers in Predicting Clinical Stage T1 Renal Cell Carcinoma Pathologically Upstaged to T3a

被引:11
|
作者
Liu, Hailang [1 ]
Wang, Zhixian [1 ]
Peng, Ejun [1 ]
Chen, Zhiqiang [1 ]
Tang, Kun [1 ]
Xia, Ding [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Urol, Tongji Med Coll, Wuhan, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
renal cell carcinoma; inflammatory markers; nephrometry score; upstaging; pathology; PREOPERATIVE SERUM-CHOLESTEROL; ROBOTIC PARTIAL NEPHRECTOMY; PT3A DISEASE; SURVIVAL; PROGNOSIS; OUTCOMES; MASSES; RISK;
D O I
10.3389/fonc.2021.679536
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives We aimed to determine preoperative risk factors associated with pathologic T3a (pT3a) upstaging of clinical T1 (cT1) renal cell carcinomas (RCCs) and develop a novel model capable of accurately identifying those patients at high risk of harboring occult pT3a characteristics. Methods A retrospective analysis of 1324 cT1 RCC patients who underwent partial nephrectomy (PN) or radical nephrectomy (RN) was performed. The study cohort was divided into training and testing datasets in a 70:30 ratio for further analysis. Univariable and multivariable logistic regression analyses were performed to identify predictors associated with cT1 to pT3a upstaging and subsequently, those significant risk factors were used to construct models. We used the area under the curve (AUC) to determine the model with the highest discrimination power. Decision curve analyses (DCAs) were applied to evaluate clinical net benefit associated with using the predictive models. Results The rates of upstaging were 6.1% (n = 81), 5.8% (n = 54) and 6.8% (n = 27) in the total population, training cohort and validation cohort, respectively. Tumor size, clinical T stage, R.E.N.A.L. (radius, exophytic/endophytic properties, nearness of tumor to collecting system or sinus, anterior/posterior) nephrometry score, lymphocyte to monocyte ratio (LMR), prognostic nutrition index (PNI) and albumin to globulin ratio (AGR) were significantly associated with pT3a upstaging. The model that consisted of R.E.N.A.L. score, LMR, AGR and PNI achieved the highest AUC of 0.70 in the validation cohort and yielded the highest net benefit. In the subpopulation with complete serum lipid profile, the inclusion of low-density lipoprotein cholesterol (LDL-C) and Castelli risk index-I (CRI-I) significantly improved the discrimination of model (AUC = 0.86). Conclusions Our finding highlights the importance of systemic inflammation response markers and serum lipid parameters in predicting pT3a upstaging. Our model had relatively good discrimination in predicting occult pT3a disease among patients with cT1 renal lesions, and the use of the model may be greatly beneficial to urologists in risk stratification and management decisions.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Does renal cell carcinoma stage T3a embrace a homogenous group of patients?
    Gofrit, Ofer N.
    Shapiro, Amos
    Pizov, Galina
    Landau, Ezekiel H.
    Katz, Ran
    Zorn, Kevin C.
    Pode, Dov
    JOURNAL OF UROLOGY, 2007, 177 (04): : 367 - 367
  • [32] Prognostic Evaluation of the Site of Invasion in Pathological Stage T3a Renal Cell Carcinoma
    Lai, Gu-Shun
    Li, Jian-Ri
    Wang, Shian-Shiang
    Chen, Chuan-Shu
    Yang, Chun-Kuang
    Hung, Sheng-Chun
    Cheng, Chen-Li
    Ou, Yen-Chuan
    Chiu, Kun-Yuan
    IN VIVO, 2021, 35 (02): : 1083 - 1089
  • [33] Current TNM classification of renal cell carcinoma evaluated:: Revising stage T3a
    Siemer, S
    Lehmann, J
    Loch, A
    Becker, F
    Stein, U
    Schneider, G
    Ziegler, M
    Stöckle, M
    JOURNAL OF UROLOGY, 2005, 173 (01): : 33 - 37
  • [34] Does stage T3a renal cell carcinoma embrace a homogeneous group of patients?
    Gofrit, Ofer N.
    Shapiro, Amos
    Pizov, Galina
    Landau, Ezekiel H.
    Katz, Ran
    Zorn, Kevin C.
    Pode, Dov
    JOURNAL OF UROLOGY, 2007, 177 (05): : 1682 - 1686
  • [35] Comparison and development of preoperative systemic inflammation markers-based models for the prediction of unfavorable pathology in newly diagnosed clinical T1 renal cell carcinoma
    Liu, Hailang
    Tang, Kun
    Chen, Zhiqiang
    Li, Zhen
    Meng, Xiaoyan
    Xia, Ding
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 225
  • [36] PROGNOSTIC STRATIFICATION OF PATHOLOGIC STAGE T3A RENAL CELL CARCINOMA AFTER RADICAL NEPHRECTOMY
    Alom, Manaf
    Shah, Paras
    Moreira, Daniel
    George, Arvin
    Waingankar, Nikhil
    Sohval, Sophie
    Jelloul, Fatima-Zahra
    Yaskiv, Oksana
    Schwartz, Michael
    Vira, Manish
    Steckel, Joph
    Richstone, Lee
    Kavoussi, Louis
    JOURNAL OF UROLOGY, 2016, 195 (04): : E1179 - E1180
  • [37] Editorial Comment to Outcomes and predictors of clinical T1 renal mass (cT1) upstaged to pathological T3a (pT3a) after partial nephrectomy: A single-center experience
    Kondo, Tsunenori
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (03) : 257 - 258
  • [38] Outcomes of partial and radical nephrectomy in patients with pathological T3a upstaging of clinical T1 renal cell carcinoma: an analysis from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort
    Fukuda, S.
    Kobayashi, M.
    Chen, W.
    Fujiwara, M.
    Nakamura, Y.
    Ishikawa, Y.
    Nakayama, A.
    Meagher, M.
    Patil, D.
    Waseda, Y.
    Tanaka, H.
    Yoshida, S.
    Saito, K.
    Derweesh, I. H.
    Master, V. A.
    Fujii, Y.
    EUROPEAN UROLOGY, 2024, 85 : S2167 - S2168
  • [39] KIDNEY TUMORS WITH RENAL VEIN BRANCH EXTENSION: INITIAL EXPERIENCE ON T3A SUB CLASSIFICATION IN UPSTAGED T1A MASSES
    Zuluaga, Laura
    Ucpinar, Burak
    Okhawere, Kennedy
    JordanRich
    Saini, Indu
    Levieddin, Josh
    Deluxe, Antony
    Badani, Ketan
    JOURNAL OF UROLOGY, 2023, 209 : E426 - E426
  • [40] Current TNM-classification of renal cell carcinoma (RCC) evaluated -: Abandoning stage T3a
    Siemer, S
    Lehmann, J
    Becker, F
    Stöckle, M
    JOURNAL OF UROLOGY, 2004, 171 (04): : 472 - 472